NL2032919B1 - Application of eurycomanol in preparation of drug, food product and health care product for preventing and treating chronic non-bacterial prostatitis - Google Patents
Application of eurycomanol in preparation of drug, food product and health care product for preventing and treating chronic non-bacterial prostatitis Download PDFInfo
- Publication number
- NL2032919B1 NL2032919B1 NL2032919A NL2032919A NL2032919B1 NL 2032919 B1 NL2032919 B1 NL 2032919B1 NL 2032919 A NL2032919 A NL 2032919A NL 2032919 A NL2032919 A NL 2032919A NL 2032919 B1 NL2032919 B1 NL 2032919B1
- Authority
- NL
- Netherlands
- Prior art keywords
- eurycomanol
- agent
- preparation
- chronic non
- drug
- Prior art date
Links
- QPHFGJSVJHRLFM-KKSWBDSZSA-N (1R,4R,5R,7R,8R,11R,13S,16S,17S,18S,19R)-4,5,7,8,16,17-hexahydroxy-14,18-dimethyl-6-methylidene-3,10-dioxapentacyclo[9.8.0.01,7.04,19.013,18]nonadec-14-en-9-one Chemical compound O1C(=O)[C@H](O)[C@@]2(O)C(=C)[C@@H](O)[C@@]3(O)[C@@H]4[C@@]5(C)[C@H](O)[C@@H](O)C=C(C)[C@@H]5C[C@@H]1[C@]42CO3 QPHFGJSVJHRLFM-KKSWBDSZSA-N 0.000 title claims abstract description 42
- QPHFGJSVJHRLFM-UHFFFAOYSA-N Eurycomanol Natural products O1C(=O)C(O)C2(O)C(=C)C(O)C3(O)C4C5(C)C(O)C(O)C=C(C)C5CC1C42CO3 QPHFGJSVJHRLFM-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 230000001684 chronic effect Effects 0.000 title claims abstract description 18
- 206010069918 Bacterial prostatitis Diseases 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 235000013305 food Nutrition 0.000 title claims abstract description 10
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 239000002250 absorbent Substances 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims description 2
- 230000000181 anti-adherent effect Effects 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- 239000013530 defoamer Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000004088 foaming agent Substances 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000003380 propellant Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000000853 adhesive Substances 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000008961 swelling Effects 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 239000008096 xylene Substances 0.000 abstract description 3
- 210000001015 abdomen Anatomy 0.000 abstract description 2
- 238000001356 surgical procedure Methods 0.000 abstract description 2
- 210000002307 prostate Anatomy 0.000 description 25
- 241000700159 Rattus Species 0.000 description 14
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 201000007094 prostatitis Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- -1 diterpenoid compound Chemical class 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000001703 glandular epithelial cell Anatomy 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention discloses an application of Eurycomanol in preparation of a drug, a food product and a health care product for preventing and treating a chronic non—bacterial prostatitis. According to the present invention, an incision test of a lower abdomen of a male rat under an aseptic surgery and inflammation and swelling of a rat auricle caused by xylene show that the Eurycomanol has good anti—inflammatory and prevention and treatment effects of the chronic non—bacterial prostatitis when applied and taken orally, and the applicable range of the Eurycomanol is improved.
Description
APPLICATION OF EURYCOMANCL IN PREPARATION OF DRUG, FOOD PRODUCT
AND HEALTH CARE PRODUCT FOR PREVENTING AND TREATING CHRONIC NON-
BACTERIAL PROSTATITIS
The present invention relates to the technical field of new uses of drugs, in particular to an application of Eurycomanol in preparation of a drug, a food product and a health care product for preventing and treating a chronic non-bacterial prostatitis.
A prostate is one of main accessory gonads in men, and a prostatitis is a group of diseases with pain in a pelvic area or symptoms of urination discomfort, which mainly occurs in young men in 20-40 years old, and is a multiple disease of which the inci- dence is about 25%-30% in urology. A chronic non-bacterial prosta- titis (CNP) is the most common type of the prostatitis, accounting for more than 90% of the incidence of the clinical prostatitis.
Although there are various treatment methods, it is difficult to cure and easy to relapse. It beings great pain to patients, and becomes one of intractable diseases of worldwide concern.
Eurycomancl, an active ingredient of Tongkat Ali, is a diterpenoid compound, the chemical formula is C:;3Hzs05, the molecu- lar weight is 410.415, and the Chemical Abstracts Service (CAS) number is 84633-28-3. In the prior art, the Eurycomanol has the efficacy of preventing malaria, removing dampness and jaundice, sterilization and anti-ulcer, and also has the efficacy of improv- ing hypertension and diabetes, but the prior art does not record what effect the Eurycomanol further has. The structural formula of the Eurycomanol is shown in FIG. 2.
A purpose of the present invention is to provide an applica- tion of Eurycomanol in preparation of a drug, a food product and a health care product for preventing and treating a chronic non-
bacterial prostatitis, and provide a new use of the Eurycomanol.
In order to achieve the above technical purpose, technical schemes of the present invention are as follows:
The Eurycomanol is applied in preparation of an anti- inflammatory drug, food product or health care product.
In a further improvement, the Eurycomanol is used to prepare a drug for preventing and treating the chronic non-bacterial pros- tatitis.
In a further improvement, the drug includes the Eurycomanol and a drug auxiliary material.
In a further improvement, the dosage form of the drug in- cludes an injection, a capsule, a tablet, an ointment, a granule, a dispersant, a solution, an emulsion, a suspension, a patch, a gel and a suppository.
In a further improvement, the drug auxiliary material in- cludes a solvent, a propellant, a solubilizer, a cosolvent, an emulgator, a colorant, a binder, a disintegrant, a filler, a lub- ricant, a wetting agent, an osmotic pressure regulator, a stabi- lizer, a glidant, a corrigent, a preservative, a suspending agent, a coating material, a fragrance, an anti-adhesive, an integration agent, a penetration enhancer, a pH adjuster, a buffer, a plasti- cizer, a surfactant, a foaming agent, a defoamer, a thickener, an inclusion agent, a humectant, an absorbent, a diluent, a floccu- lant and a deflocculant, a filter aid, and a release retardant.
In a further improvement, the Eurycomanol is used to prepare a food product for auxiliary prevention and treatment of the chronic non-bacterial prostatitis.
In a further improvement, the Eurycomanol is applied in prep- aration of a health care product for the auxiliary prevention and treatment of the chronic non-bacterial prostatitis.
FIG. 1 shows an effect of Eurycomanol on prostate H&E stain- ing; and
FIG. 2 is a structural formula diagram of the Eurycomancl.
The application of the Eurycomanol of the present invention in the preparation of the drug, food product and health care prod- uct for preventing and treating the chronic non-bacterial prosta- titis is further described in detail below in combination with specific embodiments, and technical schemes of the present inven- tion include but not limited to the following embodiments:
Embodiment 1: Effect of Eurycomanol on inflammation and swelling of mouse auricle caused by xylene 50 male mice with a body weight of {20+2}) g are taken, ran- domly divided into 5 groups, and administered by intragastric ad- ministration according to Table 1, once a day for 7 consecutive days. In 1 h after the last administration, 0.03 mL of xylene is dropwise added to a right ear of the mouse, and a left ear is not painted as a control. After 2 h, the mice are sacrificed by neck dislocation, and round ear pieces are respectively punched in the same part of the left and right ears with a hole punch with a di- ameter of 9 mm, and weighed. A difference between the left and right ear pieces is calculated as a swelling degree, and the dif- ferences between the groups are compared. Results are shown in Ta- ble 1.
Table 1: Effect of inflammation and swelling of mouse auricle caused by zylene (n=10, X*SD) “Group Amimal Dose Auriclesweling Inhibition (only) (mg/kg) degree (mg) rate{%) -— “Controlgrowp 10 1351
Indomethacin 10 40 5.242 3%%* 61.48
Eurycomanol 10 40 5.5£3.2** 59.26
Eurycomanol 10 10 11.143.2% 17.78
Compared with the control group, **P<0.01, and *P<0.05.
It may be seen from Table 1 that Eurycomanol high, medium and low doses all have the significant inhibitory effects on the in- flammation and swelling of the mouse auricles caused by the xy- lene, it is indicated that they all have the significant anti- inflammatory effects. Similarly, the positive control drug indo- methacin also has the significant anti-inflammatory effect after intragastric administration.
Embodiment 2: Therapeutic effect of Eurycomanol on experi- mental chronic non-bacterial prostatitis in animal 60 male rats are taken, randomly divided into 6 groups, and anesthetized with 3% sodium pentobarbital by intraperitoneal anes- thesia. Under an aseptic surgery, a lower abdomen is incised, and 50 microliters of a complete Freund's adjuvant is injected into each of left and right ventral lobes of a prostate, while 50 mi- croliters of normal saline is injected to each of the left and right ventral lobes of the prostate in the normal control group.
It is sutured layer by layer with an absorbable suture, to close an abdominal cavity, and the rats are resuscitated on a laboratory table at 37 degrees Celsius. The rats are given with Eurycomanol by intragastric administration once a day (the Eurycomanol, with a purity of 98%, is prepared into a suspension with 0.5% sodium car- boxymethyl cellulose solution, and stored in a refrigerator at 4 degrees Celsius). The experimental grouping and administration doses are shown in Table 2, and there is a total of 28 days of ad- ministration. On the 29-th day, all rats are weighed, then anes- thetized with 1% sodium pentobarbital intraperitoneally, and blood is taken from an abdominal femoral artery by a negative pressure tube. Adipose tissues and envelopes coated on the surface of the prostate, and a seminiferous duct on the back are separated, the prostate is completely taken down, cleanly washed with normal sa- line, wipe-dried with sterile gauze, and weighed. Sample treat- ment: after standing for several hours, a blood sample is centri-
fuged to obtain a supernatant which is serum, and it is frozen at -80 degrees Celsius for future use; after prostate tissues are weighed, it is cut into small pieces with clean scissors, and most of them are placed in a cryopreservation tube, and immediately put 5 into liquid nitrogen for quick freezing for half an hour, and then transferred to -80 degrees Celsius for cryopreservation and future use; and a part is reserved for paraffin embedding, and fixed in prepared 4% paraformaldehyde solution.
Table 2: Effect of Eurycomanol on prostate index of rats with chronic non-bacterial prostatitis (n=10, X+SD)
Group Ani- Dose Body weight Body weight of Prostate weight Prostate mal {mg/ ofrat before ratafteradmin- (mg) index (only) kg} modeling (g} istration (g) {mg/g}
Control group 10 201.70+4.28 414.41+13.26 474.00£39.61 1.15+0.11
Model group 10 204.10+3.02 368.54+12.16 1014.70150.404 2.760.214
Prostate aid 10 1000 203.42+2.61 380.34111.14 715.40+30,39* 1.88+0.10*
Eurycomanol 10 100 205.34+4.42 359.44+8.84 706.00124.14* 1.77+0.07*
Eurycomanol 10 50 204.62+2.97 394.83+11.15 716.60+31.86* 1.82+0.10*
Eurycomanol 10 25 203.81+3.03 374.27114.61 818.30+£18.80* 2.19+0.10*
Compared with a model group, *P<0.05; and compared with a blank group, 2 P<0.05.
It may be seen from Table 2 that, compared with the normal control group, the prostate index of the rats in the model group is significantly increased, it is indicated that this modeling method has an effect on the normal growth of the prostates of the experimental rat. Compared with the model group, the prostate in- dex of a prostate aid group and high and medium dose Eurycomanol group is significantly lower than that of the model control group {P<0.05).
Table 3: Effect of Eurycomanol on TNF-o and IL-6 in serum of rat with chronic nonbacterial prostatitis (n=10, X+SD)
“Group Ammal Dose TNFa (pg/mh IL-6 (pg/ml) (only) (mg/kg)
Controlgroup 10 423.78+4432 67.90¢833
Model group 10 573.16120.5344 124.55+9.6244
Prostate aid 10 1000 519.58129.08* 81.7817.85**
Eurycomanol 10 100 463.23+25.00** 78.7517.89%*
Eurycomanol 10 50 486.35+18.11** 91.4118.54**
Eurycomanol 10 25 525.24+18.59 110.98+6.54*
Compared with the model group, *P<0.05; and compared with the blank group, 2 P<0.05.
It may be seen from Table 3 that, compared with the normal control group, the levels of TNF-a and IL-6 in the serum of the rats in the model group are significantly increased (P<0.01). Com- pared with the model group, both the high and medium dose Euryco- manol groups may significantly reduce the levels of TNF-a and IL-6 in the serum of the model rats (P<0.01), and the prostate aid group may also significantly reduce the level of TNF-o in the se- rum of the model rats (P<0.05), and significantly reduce the level of IL-6 (P<0.01)}), and low-dose Eurycomanol may significantly re- duce the level of IL-6 in the serum (P<0.05).
It may be seen from FIG. 1 that glands in prostate parenchyma of the rats in the blank group are normal in arrangement and dis- tribution, and large in number; the acinar morphology is irregu- lar, with many pleated skirts, and pink secretions may be seen in the cavity, namely a prostate coagulation; and a smooth muscle may be seen in a interstitial connective tissue, and no inflammatory cell infiltration is seen. The number of acini in the prostate pa- renchyma of the rats in the model group is significantly reduced, the cavity is reduced, the prostate coagulation in the glandular cavity is significantly reduced, or even disappeared, the glandu- lar epithelium is focal necrosis and shedding, a glandular cavity basement membrane is destroyed, and there are a large number of inflammatory cells and exfoliated glandular epithelial cells. The number of the acini in the prostate parenchyma of the rats in the prostate aid group is significantly reduced, the cavity is re-
duced, the prostate coagulation in the gland cavity is signifi- cantly reduced, and there is more inflammatory cell infiltration.
The overall histological structure of the prostate in the Euryco- manol group is improved, and dose-related, and the number of the inflammatory cell infiltration is significantly decreased.
It may be concluded from the above embodiments that the Eury- comanol may effectively treat the chronic non-bacterial prostati- tis, and the present invention provides a new use of the Eurycoma- nol.
The above are only preferred implementation modes of the pre- sent invention. It should be pointed out that for those skilled in the art, without departing from the principles of the present in- vention, several improvements and modifications may be made, and these improvements and modifications should be also regarded as a scope of protection of the present invention.
Claims (7)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210227599.7A CN114469936A (en) | 2022-03-08 | 2022-03-08 | Application of Eurycomanol in preparation of medicines, foods and health products for preventing and treating nonbacterial prostatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL2032919B1 true NL2032919B1 (en) | 2023-09-18 |
Family
ID=81486566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL2032919A NL2032919B1 (en) | 2022-03-08 | 2022-08-31 | Application of eurycomanol in preparation of drug, food product and health care product for preventing and treating chronic non-bacterial prostatitis |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN114469936A (en) |
| NL (1) | NL2032919B1 (en) |
| ZA (1) | ZA202209545B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113197923A (en) * | 2021-05-11 | 2021-08-03 | 湘南学院 | Eurycoma longifolia extract and application thereof in medicines for preventing and treating prostatitis |
-
2022
- 2022-03-08 CN CN202210227599.7A patent/CN114469936A/en not_active Withdrawn
- 2022-08-26 ZA ZA2022/09545A patent/ZA202209545B/en unknown
- 2022-08-31 NL NL2032919A patent/NL2032919B1/en active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113197923A (en) * | 2021-05-11 | 2021-08-03 | 湘南学院 | Eurycoma longifolia extract and application thereof in medicines for preventing and treating prostatitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114469936A (en) | 2022-05-13 |
| ZA202209545B (en) | 2022-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080279820A1 (en) | Compositions and Methods for Treating Burns | |
| Creech et al. | Treatment of melanoma by isolation-perfusion technique | |
| US20100266709A1 (en) | Compositions and Methods for Treating Burns | |
| PH26827A (en) | A locally administrable therapeutic composition for inflammatory disease | |
| EP2292257A2 (en) | Compositions and methods for dermatological wound healing | |
| WO1999059634A1 (en) | Anti-inflammatory eye drops | |
| US11471501B2 (en) | Pharmaceutical composition for use in the treatment of prostate pathologies | |
| WO2007123867A2 (en) | Stable solutions of prostaglandin and uses of same | |
| TW200304829A (en) | Pharmaceutical composition comprising a C1C-2 channel opener | |
| NL2032919B1 (en) | Application of eurycomanol in preparation of drug, food product and health care product for preventing and treating chronic non-bacterial prostatitis | |
| CAVANAGH | Herpetic ocular disease: therapy of persistent epithelial defects | |
| McNALLY | Cough due to captopril. | |
| EP1806136B1 (en) | Medicinal composition for prevention of transition to operative treatment for prostatic hypertrophy | |
| JP2005029529A (en) | Therapeutic agent for hemorrhoid | |
| WO1992020333A1 (en) | Use of formoterol for treatment of tissue injury | |
| JPH10218792A (en) | Agent for promoting secretion of lacrimation and treating keratoconjunctive disorder containing angiotensin converting enzyme as active ingredient | |
| CN109568317B (en) | Omeprazole compound preparation | |
| Selye | On the mechanism through which obstructive jaundice influences inflammatory processes | |
| Schweitzer | Purulent pericarditis: Management with surgical drainage and enzymatic débridement | |
| AU2023263539A1 (en) | Compositions and uses therefor | |
| Dockery et al. | Another Comment on:“Microscope-Integrated Optical Coherence Tomography-guided Drainage of Acute Corneal Hydrops in Keratoconus Combined with Suturing and Gas-aided Reattachment of Descemet Membrane” | |
| RU2121323C1 (en) | Solution "keratane c" for treatment of patients with sickness and damage of cornea | |
| US20230057930A1 (en) | Compositions for alleviating the symptoms of low anterior resection syndrome by topical administration to the neorectum | |
| JP2023522921A (en) | A novel treatment for acute injury to lung tissue | |
| CN117064901A (en) | Pharmaceutical composition for treating lymphedema |